UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011567
Receipt number R000013521
Scientific Title The efficancy of a new long-acting insulin degludec in patient with diabetes
Date of disclosure of the study information 2013/08/31
Last modified on 2015/08/23 16:00:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficancy of a new long-acting insulin degludec in patient with diabetes

Acronym

The efficancy of a new long-acting insulin degludec in patient with diabetes

Scientific Title

The efficancy of a new long-acting insulin degludec in patient with diabetes

Scientific Title:Acronym

The efficancy of a new long-acting insulin degludec in patient with diabetes

Region

Japan


Condition

Condition

diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare an new long-acting insulin degludec with the existing diabetes therapeutic drug for efficancy and safety in diabetes

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in HbA1c and the score of Diabetes Treatment Satisfaction Questionnaire and dietary behavior Questionnaire , ITNA-1 and adverse events including hypoglycemia at 24 weeks later from an examination start

Key secondary outcomes

From an examination start, it is the following items 48 weeks later for up to 24 weeks.
-Achievement rate of HbA1c <7.0% and <8.0%
-Change in fasting blood glucose
-Glycemic variability by CGM and SMBG
-Change in insulin dose(daily basal insulin doses, daily total insulin doses)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

insulin degludec

Interventions/Control_2

Continuing with the treatment so far

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

HbA1c :more than 8.0%

Key exclusion criteria

Contraindicated patient in the attached document of insulin degludec
Contraindicated patient in the attached document of diabetes drugs
Hypoglycemic risk
Serious heart trouble
Severe hepatic dysfunction
Severe renal dysfunction
Internal secretion disease
Needs the steroid dosage
Patients judged by the investigator to be ineligible for some other reason

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koichiro Yasuda

Organization

Osaka Saiseikai Noe Hospital

Division name

Department of Diabetes and Endocrinology

Zip code


Address

1-3-25, Furuichi, Jyoto-ku, Osaka-shi, Osaka, 536-0001, Japan

TEL

06-6932-0401

Email

kyasuda@noe.saiseikai.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Motoya Koie

Organization

Osaka Saiseikai Noe Hospital

Division name

Department of Diabetes and Endocrinology

Zip code


Address

1-3-25, Furuichi, Jyoto-ku, Osaka-shi, Osaka, 536-0001, Japan

TEL

06-6932-0401

Homepage URL


Email

motoya.koie@noe.saiseikai.or.jp


Sponsor or person

Institute

Osaka Saiseikai Noe Hospital

Institute

Department

Personal name



Funding Source

Organization

Osaka Saiseikai Noe Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪府済生会野江病院(大阪府) /Osaka Saiseikai Noe Hospital(Osaka)


Other administrative information

Date of disclosure of the study information

2013 Year 08 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2013 Year 03 Month 14 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 08 Month 23 Day

Last modified on

2015 Year 08 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013521


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name